35 results on '"KISH, JONATHAN"'
Search Results
2. Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among U.S. patients with lower-risk myelodysplastic syndromes (LR-MDS).
3. Monitoring and management of interstitial lung disease/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan.
4. US physician perceptions of treatment decision making for advanced renal cell carcinoma.
5. Racial disparity in uterine cancer treatment and survival: A matter of Black women’s lives.
6. Real-world clinical effectiveness of eribulin in metastatic breast cancer patients with visceral metastases in the United States.
7. Real-world utilization of quality-of-life data: Perspectives from community oncology providers.
8. Linking reimbursement to patient-reported quality of life: Provider perspectives.
9. Impact of augmented intelligence (AI) on identification and management of depression in oncology.
10. Real-world disease burden for patients (pts) with myelofibrosis (MF) treated with ruxolitinib (RUX).
11. Prescribing preferences for hormone sensitive (HR+) metastatic breast cancer (mBC) in the CDK 4/6 inhibitor (CDK 4/6i) era.
12. Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).
13. Gender-based disparities in clinical trials supporting FDA approval of oncology drugs.
14. Physician treatment preferences for metastatic triple negative breast cancer (mTNBC) in an era of immunotherapy.
15. Impact of augmented intelligence (AI) on utilization of palliative care (PC) services in oncology.
16. Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.
17. Community oncologists' perceptions three years after the Oncology Care Model.
18. Real-world evidence evaluating the use of single versus combination chemotherapy in salvage therapy for metastatic breast cancer.
19. Artificial intelligence (AI) to improve patient outcomes in community oncology practices.
20. Use of a granulocyte colony-stimulating factor for the prevention of febrile neutropenia in the era of value-based care.
21. Real-world evidence evaluating the use of an NK-1 antiemetic in the systemic chemotherapy treatment of metastatic breast cancer.
22. Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.
23. Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) targeted therapy (TT) or immuno-oncology (I-O) agents at US-based community oncology practices.
24. Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF+ MM) patients receiving first-line (1L) treatment with dabrafenib/trametinib (D+T) v ipilimumab/nivolumab (I+N) and nivolumab or pembrolizumab (N/P) monotherapy at US-based community oncology practices.
25. Real-world evidence (RWE) to show improved time to progression among resected pancreatic cancer (RPC) patients receiving adjuvant chemotherapy (adjch).
26. Opportunities for improving outcomes in pancreatic cancer patients: Characterizing the unresected “resectable” population.
27. Evaluation of real-world electronic medical record (EMR) treatment outcome data compared to clinical trial data for an advanced breast cancer treatment.
28. Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies.
29. Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience.
30. Surgical, radiological, and chemotherapy treatment patterns for non-metastatic and metastatic gastric cancer.
31. Adherence to chemotherapy guidelines for non-metastatic (NM) and metastatic (M) colorectal cancer (CRC).
32. Adherence to guideline-recommended chemotherapy in the treatment of gastric cancer.
33. Opioid use among prostate cancer patients with bone metastases.
34. Evaluation of national treatment trends in ovarian cancer.
35. Disconnect between earlier presentation patterns and application of curative treatments in HCC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.